Tek doz venlafaksin kullanımına bağlı gelişen Nöroleptik malign sendrom

Nöroleptik malign sendrom (NMS) antipsikotik tedavinin nadir görülen fakat potansiyel olarak hayatı tehdit eden bir komplikasyonudur. NMS ço ğ unlukla kendisini ekstra- piramidal bulgular, hiperrefleksi, bilinç ve kan bası nc ı de ğ iş iklikleri ş eklinde gösteren bir tablodur. Ate ş , kas rijiditesi, tremor, otonomik disregülasyon bulgular ı , mental durum de ğ iş ikliğ i ve laboratuar anomalileriyle (yükselmiş kreatin fosfokinaz, polimorfonükleer lökositozis, yükselmiş karaciğ er enzimleri ve myoglobinüri) karakterize bir tablodur. Genellikle antipsikotik kullan ı m ı na ba ğ l ı olarak ortaya çı kar. Biz bu yaz ı da tek doz venlafaksin al ı m ı na ba ğ l ı geliş en nöroleptik malign sendrom vakas ı n ı sunmayı amaçlad ı k.

Neuroleptic malignant syndrome that develops with using of a single dose venlafaxine

Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening complication of antipsychotic medication. NMS shows itself with extrapyramidal symptoms, hyperreflexia, changes in consciousness and blood pressure. It is a condition thats characterized by fever, muscular rigidity, tremor, the autonomical dysregulation symptoms, mental status changes and laboratory abnormalities (elevated creatine phosphoki- nase, polymorphonuclear leucocytosis, elevated liver enymes and myoglobinuria). NMS is commonly triggered by antipsychotic drug use. Herein we aimed to present a case report about neuroleptic malignant syndrom that develops with using of a single dose venlafaksin.

PDF

___

1. Védie C, Poinso F, Hemmi F, Rivet B. Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports. Eur Psychiatry 2000;15:334-7.
2. Fekadu A, Bisson JI. Neuroleptic malignant syndrome: Diagnostic and therapeutic dilemmas. Behav Neurol 2005;16:9-13.
3. İşeri P, Selekler M. Noroleptik malign sendrom. Turkiye Klinikleri J Int Med Sci 2005;1:39-42.
4. Delay J, Deniker P. Drug-induced extra-pyramidal syndromes. In Handbook of Clinical Neurology. Vol. 6: Diseases of the Basal Ganglia (Eds PS Vinken, GW Bruyn): 248266. North-Holland, New York, Elsevier, 1968.
5. Sarkar P, Natarajan C, Gode N. Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients. Indian J Psychiatry 2009;51:202-5.
6. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-92. 1. 7.Caroff SN, Rosenberg H, Mann SC, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in the critical care unit. Crit Care Med 2002;30:260910.
7. Langlow JR, Alarcon RD. Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. J Clin Psychiatry 1989;50:144-5.
8. Gupta S, Racaniello AA. Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult. Ann Clin Psychiatry 2000;12:107-9.
9. Tsai HC, Kuo PH, Yang PC. Fever, consciousness disturbance, and muscle rigidity in a 68-year-old man with depressive disorder. Chest 2003;124:1598-601.
10. Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant syndrome after venlafaxine. Lancet 2000;354:289-90.
11. Lu TC, Chu PL, Wu CS, Tsai KC, Chen WJ. Neuroleptic malignant syndrome after the use of venlafaksin in a patient with generalized anxiety disorder. J Formos Med Assoc 2006;105:90-3.
12. Redrobe, JP, Bourin M, Colombel MC, Baker GB. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 1998;138:18.
13. Goldberg RJ. Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Family Med 1998; 7:7884.
14. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003;169:43
15. Doğan N, Kürşad H, Erdem AF, Kızılkaya M. Noroleptik malign sendromda nadir etyolojik faktorler ve klinik seyir. AUTD 2003;35:23-6.
16. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome. Psychiatr Serv 1998; 49:1163-72.
17. Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999;2:129- 144.
18. Taniguchi N, Tanii H, Nishikawa T. Classification system of complications in neuroleptic malignant syndrome. Methods Find Exp Clin Pharmacol 1997;19:193-9.
19. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25.
20. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464-70.
21. Simon HB. Hyperthermia. N Engl J Med 1993;329:483-7.
22. Stahl MS. Essential Psychopharmacology. Cambridge: Cambridge University 2000; p:245-97.
23. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. Eleventh ed. Hudson, OH: Lexi-Comp, 2003.
24. Woods G, Taggart C, Boggs R, Cadden I. Neuroleptic malignant syndrome associated with quetiapine and venlafaxine use: a case report and discussion. Ther Adv Psychopharmacol 2013;3:53-5.
25. Mannaioni G, Baronti R, Moroni F. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Ther Clin Risk Manag 2005;1:225-9.